DIRS.INFO The most relevant business & tech news

☆ J&J's 2025 drug sales forecast should not be tripping up investors. There's so much else like
▼ + stars: | 2023-04-18 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

Johnson & Johnson (JNJ) before-the-bell Tuesday reported a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase. We're leaning toward the second reason: Management's 2025 Pharmaceutical sales target because J & J's results would have exceeded estimates even without strong vaccine sales. On the post-earning call, management said they see Pharmaceutical sales in 2025 closer to $57 billion than the $60 billion forecast two years ago. While we understand the Street's desire to dig into the 2025 Pharmaceutical sales dynamic, we believe weakness in the stock represents a buying opportunity. That's thanks to increased prices and strong consumer demand, the combination of which speaks to the pricing power of the Johnson & Johnson, soon-to-be Kenvue, brand.

☆ Earnings from Club consumer, health and bank stocks will be our main focus in the week ahead
▼ + stars: | 2023-04-15 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Corporate earnings won't have to share the spotlight with major inflation data in the week ahead as they did during this past week's up-and-down market. From Morgan Stanley, we suspect Friday's bank earnings foreshadow a good release. This past week, we spoke about the importance of listening to what industry players aside from those you're invested in as a way to analyze the competitive landscape. Here are some of those other earnings reports and the economic numbers out in the week ahead. Club trades of the week We made just one trade this past week, in a market that was overbought , purchasing 25 shares of Palo Alto Networks (PANW).

☆ White House plans support for drugstores, pharma in abortion pill battle
▼ + stars: | 2023-04-09 | by ( Nandita Bose | ) www.reuters.com time to read: +4 min

"We are discussing ways to offer them legal support," one of the sources said of manufacturers and retail pharmacies. Major U.S. manufacturers of abortion pills include GenBioPro Inc and Danco Laboratories. Walgreens said in March it would not dispense abortion pills in the 20 states where it risked breaking the law. Discussions between the Biden administration and pill manufacturers and pharmacies over the issue have been ongoing for months, sources said, but Friday's decision brings fresh urgency. It is unclear whether the administration is considering following in California Governor Gavin Newsom's footsteps by withholding federal contracts from chains that suspend abortion pill sales.

Pfizer CEO Albert Bourla speaks during the China Development Forum in Beijing on March 25, 2023. BEIJING — U.S. pharma giant Pfizer has signed an agreement with China to cooperate on improving the country's health coverage, according to the company. China in 2016 announced a "Healthy China 2030" plan for improving the country's public health services, medical industry and food and drug safety. The Covid-19 pandemic also highlighted shortfalls in China's still-developing public health system. Pfizer's memorandum of understanding with the Health China Research Center is set to support public health research and improve the health of rural populations, according to details released by Chinese state media.

Companies Bayer AG FollowNEW YORK, March 9 (Reuters) - Bayer AG (BAYGn.DE) plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters. "It's time for us to double down on the U.S.," Guth said, noting that Bayer plans to sell the drugs it is developing itself in the country, rather than partner with U.S. companies like it has in the past. Bayer is looking to build up its portfolio of new drugs as it hopes to improve share prices, which have been hit by concerns over litigation surrounding weedkiller Roundup and a lack of trust in the company's leadership. Guth said he expects peak sales of 12 billion euros from cancer drug Nubeqa, kidney medication Kerendia, and two of its top pipeline assets, experimental stroke drug asundexian and experimental women's health drug elinzanetant. Reporting by Michael Erman; Editing by David GregorioOur Standards: The Thomson Reuters Trust Principles.

☆ Eli Lilly’s Insulin Decision Puts Others in Hot Seat
▼ + stars: | 2023-03-08 | by ( David Wainer | ) www.wsj.com time to read: +1 min

High list prices for insulin add to the profits of pharmacy-benefit managers. But when a little-known nonprofit named Civica Rx announced plans last year to make low-cost insulin, the move didn’t spook the companies that profit from high insulin prices. Pharmacy-benefit managers, which control 80% of the prescription-drug market, profit from high list prices. Keeping Civica Rx at bay is one thing. That is exactly what happened last week when Eli Lilly decided to drastically cut the list price of some of its insulin products.

☆ This week's best-performing stocks include a pharma name up more than 20%
▼ + stars: | 2023-02-10 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Wall Street is wrapping up a volatile week, but some stocks still did well despite several macro crosscurrents. Take a look at some of the biggest gainers this week, and where analysts see them going forward. Tesla was one of this week's notable gainers, continuing its post-earnings report rally. Semiconductor manufacturer and IP company Skyworks Solutions also made this week's list of biggest gainers. Several financial stocks also had a strong week, with Everest Re and Fiserv gaining 10.1% and 9.2%, respectively.

☆ Earnings playbook: Apple and Google-parent Alphabet lead the busiest week of reports
▼ + stars: | 2023-01-29 | by ( Fred Imbert | ) www.cnbc.com time to read: +14 min

Tuesday General Motors is set to report earnings before the bell, followed by a conference call at 8:30 a.m. What history shows: Data from Bespoke Investment Group shows GM beats earnings expectations 85% of the time. McDonald's is set to report earnings before the bell, with company leadership set to hold a call 8:30 a.m. What history shows: Qualcomm has either beaten or matched analysts' earnings expectations in the last 32 quarters, according to FactSet. Alphabet is set to report earnings after the close, followed by a conference call at 4:30 p.m.

☆ BioNTech says it will start cancer vaccine trials in the UK from September
▼ + stars: | 2023-01-06 | by ( Jenni Reid | ) www.cnbc.com time to read: +2 min

BioNTech is launching a large-scale trial of mRNA therapies to treat cancer and other diseases in the U.K.LONDON — The U.K. government on Friday announced a partnership with German firm BioNTech to test potential vaccines for cancer and other diseases, as campaigners warned any breakthrough must remain affordable and accessible. Cancer patients in England will get early access to trials involving personalized mRNA therapies, including cancer vaccines, which aim to spur the immune system to attack harmful cells. They will be administered to early and late-stage patients and target both active cancer cells and preventing their return. Peter Johnson, Britain's National Clinical Director for Cancer, said mRNA technology had the potential to transform approaches to a number of illnesses. The government confirmed to CNBC the announcement represented a private investment into the U.K., but would be supported by a new Cancer Vaccine Launch Pad funded by the NHS.

☆ What to watch for as J&J gets ready to split into two separate companies next year
▼ + stars: | 2022-12-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +11 min

During Monday's "Morning Meeting" for members, Jim Cramer said that J & J has the "best balance sheet in America." According to projections from J & J and rival Medtronic (MDT), the robotics market captures a low 2% to 3% of global procedures. In an economic slowdown, J & J is a solid name to own that can outperform the broader market. We also like that J & J has consistently raised its dividend. We rate J & J a 1 for the Club , meaning we would buy the stock at current levels given it aligns with our strategy.

Organizations: & $

☆ Three pharmaceutical stocks were last week's top performers — and analysts gave one 40% upside
▼ + stars: | 2022-12-05 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Global stocks rose last week, tracking U.S. stocks as Wall Street's major indexes closed with weekly gains. The MSCI World index was up about 1% over the week, and all three U.S. indexes also set weekly gains , with the Nasdaq posting the largest increase. Pharmaceutical stocks had a good week, with three — Horizon Therapeutics , Catalent and Alnylam Pharmaceuticals — making big gains. Of all three, Catalent got the highest upside (40%) from analysts — getting a buy rating from 56% of those covering the stock. U.S. media and internet company IAC was one top weekly performer, with the highest upside given by analysts — at 60%.

☆ Credit Suisse touts drug stocks as a top place to be. These are our 2 favorites
▼ + stars: | 2022-11-18 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Like the Club, Credit Suisse holds a positive view on Mounjaro — the company's diabetes drug that's shown immense promise as an obesity treatment, too — and Lilly's latest experimental Alzheimer's drug ahead of a pivotal data release expected next year. However, we differ on J & J, which will soon break itself up. The remaining J & J will be its current pharmaceutical and medical technologies divisions. Credit Suisse rates J & J as neutral with a $170 price target, which is nearly 4% below where the stock closed Thursday. A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

☆ Credit Suisse calls this group the ultimate 'refuge from stormy seas' with a recession ahead
▼ + stars: | 2022-11-18 | by ( John Melloy | ) www.cnbc.com time to read: +2 min

The firm said investors still need to be selective in the space, however, naming two top ideas in Merck and AbbVie . Credit Suisse says U.S. pharma as a group is trading at a price-earning ratio of 16 times to 17 times while defensive sectors utilities and consumer staples have 18-20 P-E ratios, on average. For AbbVie, it sees 11% upside from here, noting it has the "highest dividend yield among peers." "As such, we believe large-cap biopharma should remain a solid outperformer in the coming months, with portfolios requiring diversity in the defensive names. If markets rally on further clarity, we see our higher-growth names, such as Eli Lilly, being insulated from the rotation away from defensives and back into growth names."

☆ Big pharma not doing enough to improve drug access - analysis
▼ + stars: | 2022-11-15 | by ( Natalie Grover | ) www.reuters.com time to read: +3 min

[1/2] A doctor tests a child for malaria at the Ithani-Asheri Hospital in Arusha, Tanzania, May 11, 2016. While there has been progress, there remain some gaping holes that need to be prioritised in the coming years, Access to Medicine Foundation CEO Jayasree Iyer told Reuters. The findings mirror a long-established pattern - that the pharmaceutical industry will prioritise countries where there is a market, she said. "If we consistently see that the industry leaves low income countries behind, then we're never going to solve the problem of access at scale," she said. In terms of overall rankings on the Access to Medicine Index, British drugmaker GSK (GSK.L) retained the top spot, closely followed by U.S. pharma major Johnson & Johnson (J&J) (JNJ.N).

☆ Pfizer's India arm posts profit jump on lower costs, price hikes
▼ + stars: | 2022-11-11 | by ( ) www.reuters.com time to read: +1 min

BENGALURU, Nov 11 - Pfizer Ltd (PFIZ.NS), the Indian arm of U.S. pharma giant Pfizer Inc (PFE.N), reported a rise in second-quarter profit on Friday, boosted by price hikes and lower input costs. Profit before tax and exceptional item rose to 2.26 billion Indian rupees ($27.97 million) in the three months ended Sept. 30, from 1.75 billion rupees in the year-ago period. The company booked a one-time gain of 1.89 billion rupees on the sale its off-patent and generic medicines business, Upjohn. Pfizer's revenue from operations rose 0.3% to 6.38 billion rupees. Earlier in the day, peer Zydus Lifesciences (ZYDU.NS) reported an 82.6% slump in second-quarter profit, hit by rising expenses.

☆ BioNTech lifts lower end of vaccine sales target range
▼ + stars: | 2022-11-07 | by ( ) www.reuters.com time to read: +1 min

FRANKFURT, Nov 7 (Reuters) - COVID-19 vaccine maker BioNTech (22UAy.DE) on Monday raised the lower bound of its 2022 COVID-19 vaccine revenue guidance for the full year, citing demand for its adapted shots and higher prices. The German biotech firm, the vaccines partner of U.S. pharma giant Pfizer (PFE.N), said in a statement that it is now targeting 16 to 17 billion euros ($16-$17 billion) in vaccine sales, compared with a previous range of 13-17 billion but down from 19 billion euros reported for last year. Partner Pfizer last week raised its forecast for its 2022 sales of the COVID-19 vaccine by $2 billion to $34 billion. Sales during the July-to-September quarter dropped 43% to 3.46 billion euros while net profit fell 44% to 1.78 billion euros. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns.

☆ How the U.S. midterms could ripple through the stock market
▼ + stars: | 2022-11-07 | by ( Lewis Krauskopf | ) www.reuters.com time to read: +5 min

Regardless of the winner, past midterm elections have ushered in a period of positive market performance, something investors would welcome after a year in which the S&P 500 has declined by nearly 21%. The S&P 500 aerospace and defense index (.SPLRCAED) is up nearly 10% this year. HEALTHCAREPharmaceutical and biotech stocks may benefit in a Republican victory, after Democrats recently pushed through a law aimed at lowering prescription drug prices. The S&P 500 healthcare sector (.SPXHC) is down some 7% in 2022, while the S&P 500 pharmaceuticals index (.SPLRCCARG) is up about 1%. Therefore Republican victory in the House or Senate "probably means a legislative standstill, implying an incremental positive for the category," the said.

☆ 2 takeaways from our daily meeting: Pharma stocks under pressure, Club holdings report
▼ + stars: | 2022-11-01 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Pharma Club stocks under pressure Club earnings ahead 1. Pharma Club stocks under pressure The S & P 500 Short Range Oscillator is still over 6%, meaning the market is overbought — but there are some Club holdings under enough pressure to watch for a potential purchase. Club earnings ahead This week of earnings is jam-packed with Club names. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ An economic nightmare is a near certainty as inflation stays hot while a recession nears. UBS says to forget the normal defensive playbook and instead invest your money in these 3 industries.
▼ + stars: | 2022-10-27 | by ( James Faris | ) www.businessinsider.com time to read: +4 min

While it's unclear if there will be a severe recession, there is one outcome that investors can bank on, Parker wrote: stagflation. The market is implying a nearly 100% chance of weak economic growth paired with rampant inflation, which is a nightmarish economic scenario. UBSHowever, Parker wrote that the market selloff still has room to go as tighter financial conditions hurt estimates for earnings and economic growth. Besides interest rates, economic activity is the biggest driver of stocks right now, Parker wrote. More broadly, sectors for quality growth include consumer discretionary, healthcare, and technology, Parker wrote.

Organizations: & & /

Search resuls for: ". pharma"

19 mentions found